TY - JOUR
T1 - Selection of antimicrobial frog peptides and temporin-1DRa analogs for treatment of bacterial infections based on their cytotoxicity and differential activity against pathogens
AU - Gaiser, R.A.
AU - Ayerra Mangado, J.
AU - Mechkarska, M.
AU - Kaman, W.E.
AU - van Baarlen, P.
AU - Conlon, J.M.
AU - Wells, J.M.
PY - 2020/10
Y1 - 2020/10
N2 - Cationic, amphipathic, α‐helical host‐defense peptides (HDPs) that are naturally secreted by certain species of frogs (Anura) possess potent broad‐spectrum antimicrobial activity and show therapeutic potential as alternatives to treat infections by multi‐drug resistant pathogens. Fourteen amphibian skin peptides and twelve analogues of temporin‐1DRa were studied for their antimicrobial activities against clinically relevant human or animal skin infection‐associated pathogens. For comparison, antimicrobial potencies of frog skin peptides against a range of probiotic lactobacilli were determined. We used the VITEK 2 system to define a profile of antibiotic susceptibility for the bacterial panel. The minimal inhibitory concentration (MIC) values of the naturally occurring temporin‐1DRa, CPF‐AM1, alyteserin‐1c, hymenochirin‐2B, and hymenochirin‐4B for pathogenic bacteria were 3‐ to 9‐fold lower than the values for the tested probiotic strains. Similarly, temporin‐1DRa and its [Lys4], [Lys5] and [Aib8] analogues showed 5‐ to 6.5‐fold greater potency against the pathogens. In the case of PGLa‐AM1, XT‐7, temporin‐1DRa and its [D‐Lys8] and [Aib13] analogues, no apoptosis or necrosis was detected in human peripheral blood mononuclear cells at concentrations below or above the MIC. Given the differential activity against commensal bacteria and pathogens, some of these peptides are promising candidates for further development into therapeutics for topical treatment of skin infections
AB - Cationic, amphipathic, α‐helical host‐defense peptides (HDPs) that are naturally secreted by certain species of frogs (Anura) possess potent broad‐spectrum antimicrobial activity and show therapeutic potential as alternatives to treat infections by multi‐drug resistant pathogens. Fourteen amphibian skin peptides and twelve analogues of temporin‐1DRa were studied for their antimicrobial activities against clinically relevant human or animal skin infection‐associated pathogens. For comparison, antimicrobial potencies of frog skin peptides against a range of probiotic lactobacilli were determined. We used the VITEK 2 system to define a profile of antibiotic susceptibility for the bacterial panel. The minimal inhibitory concentration (MIC) values of the naturally occurring temporin‐1DRa, CPF‐AM1, alyteserin‐1c, hymenochirin‐2B, and hymenochirin‐4B for pathogenic bacteria were 3‐ to 9‐fold lower than the values for the tested probiotic strains. Similarly, temporin‐1DRa and its [Lys4], [Lys5] and [Aib8] analogues showed 5‐ to 6.5‐fold greater potency against the pathogens. In the case of PGLa‐AM1, XT‐7, temporin‐1DRa and its [D‐Lys8] and [Aib13] analogues, no apoptosis or necrosis was detected in human peripheral blood mononuclear cells at concentrations below or above the MIC. Given the differential activity against commensal bacteria and pathogens, some of these peptides are promising candidates for further development into therapeutics for topical treatment of skin infections
KW - Antimicrobial Peptide
KW - Biological Screening
U2 - 10.1111/cbdd.13569
DO - 10.1111/cbdd.13569
M3 - Article
VL - 96
SP - 1103
EP - 1113
JO - Chemical Biology and Drug Design
JF - Chemical Biology and Drug Design
SN - 1747-0285
IS - 4
ER -